About 20% to 40% of patients with non-small cell lung cancer (NSCLC) will establish brain metastases through the natural span of their disease. therapy following the affected person developed new human brain lesions and leptomeningeal metastasis through the maintenance therapy of gefitinib. The PFS for the second-line therapy was half a year. In total, the… Continue reading About 20% to 40% of patients with non-small cell lung cancer